NCT07682597 Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component
| NCT ID | NCT07682597 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Timothy Mullett |
| Condition | Lung Cancer Screening |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-03-01 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to reduce lung cancer-related death in underserved communities. Previous research had success with implementing interventions in Kentucky which has lead to significant increases in lung cancer screening rates and a rapid decline in late-stage lung cancer diagnoses within the state. The goal is to offer the opportunity to replicate this work in states which are eager to address suboptimal screening rates, high lung cancer-related death, and significant health equity concerns. The QUILS™ SBI intervention involves translating the success of the initial work in Kentucky to impact lung cancer screening implementation and lung cancer outcomes in MS and NV through close collaboration with state-based partners. The QUILS™ SBI intervention may be an effective way to improve the statewide capacity for implementing and sustaining lung cancer screening in MS and NV.
Eligibility Criteria
Inclusion Criteria: * Member of a state-based lung cancer screening implementation team in Mississippi or Nevada. * Leadership member of the Mississippi state team or Nevada state team * Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC) * Willing to participate in study-related assessments an implementation activities Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07682597 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Lung Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07682597 currently recruiting?
Yes, NCT07682597 is actively recruiting participants. Contact the research team at joseph.alexander@uky.edu for enrollment information.
Where is the NCT07682597 trial being conducted?
This trial is being conducted at Greenville, United States, Greenwood, United States, Gulfport, United States, Hattiesburg, United States and 9 additional locations.
Who is sponsoring the NCT07682597 clinical trial?
NCT07682597 is sponsored by Timothy Mullett. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.